Prime Minister Scott Morrison said on Monday his government has reached a deal that would see Australian biotechnology giant CSL manufacture two separate vaccines.
One is a vaccine being developed by AstraZeneca and Oxford University and trialled in Brazil, the UK and South Africa, while the other is being developed in CSL’s own labs in partnership with the University of Queensland.
Australia has announced a deal with biotech company CSL to manufacture two vaccines, one developed in-house and one developed by AstraZeneca and Oxford University. https://t.co/PbRppBTCka
— New Scientist (@newscientist) September 7, 2020
Morrison said that while the agreement “puts Australia at the top of the queue”, there were no guarantees an effective vaccine would make it to market.
If the trials prove a success, CSL is expected to supply 30 million doses of the AstraZeneca/Oxford vaccine and 51 million doses of its own vaccine to the Australian government, with the first doses to be available in early 2021.
- France and three other EU countries sign deal for AstraZeneca Covid-19 vaccines
- Pre-orders of COVID-19 vaccine top five billion
He estimated the cost of the deal, which would see vaccines be provided free of charge to Australia’s population of 25 million people, to be 1.24 billion US dollars.
The number of new daily infections in the state of Victoria, Australia’s virus hotspot, fell to a 10-week low on Monday.
More than 750 Australian have died from Covid-19 since the start of the pandemic.
